Navigation Links
FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
Date:3/2/2008

utilize anti-emetic therapy for PONV. Of these 15 million procedures, 89%, or 13.4 million, use 5-HT3 receptor antagonists, such as Aloxi.

"This is an important milestone for Aloxi, given the increasing use of antiemetic prophylaxis during surgical procedures," said Riccardo Braglia, CEO, Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, holder of the Aloxi New Drug Application and partner of Eisai Corporation of North America. MGI PHARMA, INC. licensed the North American distribution and marketing rights for Aloxi from Helsinn.

About Postoperative Nausea and Vomiting (PONV)

Postoperative nausea and vomiting are common consequences of anesthetic and surgical procedures, and frequently occur following the procedures. Patients undergoing abdominal, gynecological, ear/nose/throat, or optical procedures are at highest risk for PONV. Additional factors that can increase the risk for PONV include female gender, non-smoking status, prior history of PONV or motion sickness, length of surgery, and the use of volatile anesthetics and opioids.

About Aloxi(R) Injection

In addition to the new PONV indication, Aloxi (palonosetron HCl) injection 0.25 mg is the first and only 5-HT3 receptor antagonist to be indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and for the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. The most commonly reported adverse reactions in Aloxi chemotherapy-induced nausea and vomiting trials include headache (9%) and constipation (5%).

Please see the Aloxi package insert, available at http://www.aloxi.com, for important additional details.

About HELSINN HEALTHCARE
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
2. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
3. U.S. Court Approves AK Steels VEBA Health Care Settlement With Middletown Works Retirees
4. Securian Board Approves 8 Officer Promotions
5. MGT Capital Investments, Inc. Approves Share Buyback Program
6. Kaiser Permanente Approves $29 Million in Community Benefit Grants
7. Otter Tail Corporation Reports Record Revenues and Net Income From Continuing Operations for 2007; Earnings Per Share of $1.78; Board Approves Dividend Increase
8. Pennsylvania Attorney General Approves Vincentian Collaborative System-Marian Manor Integration
9. FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
10. FDA Approves Additional Indication for Astellas MYCAMINE(R)
11. FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part ... the latest and coolest applications on the market for ... NewsWatch and technology expert, conducted the app review and ... runner game with knights, nature, and peasants. , ... according to Eurogamer. The popularity of these games grew ...
(Date:3/28/2015)... New York, New York (PRWEB) March 28, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. ... multidistrict litigation underway in U.S. District Court, Southern ... Jeffrey S. Grand, is serving on the Plaintiffs’ ... March 24th, the Court has granted certain defendants ...
(Date:3/28/2015)... Orlando, FL (PRWEB) March 28, 2015 ... pre-existing conditions coverage is made available to all visitors ... States, effective immediately. All members are encouraged to purchase ... finalized to avoid lack of proper coverage for pre-existing ... suffer from one or two medical conditions with serious ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... correlate with a history of shoulder and elbow injuries, according ... for Sports Medicine’s ( AOSSM ) Specialty Day. , “Our ... associated with a 20% increase in likelihood of a history ... is associated with a 12% increase likelihood of a history ...
(Date:3/28/2015)... Delaying rotator cuff surgery on patients with ... presented today at the American Orthopaedic Society for Sports ... compared results for 170 patients who received rotator cuff ... capsule release procedure to relieve stiffness at the time ... from St. George Hospital in Sydney, Australia. “Both groups ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2
... a combined treatment of hormonal therapy and the drug, Herceptin ... breast cancer by over half, according to a recent report. ... the treatment to be made available for even more women ... addition of Herceptin to hormonal therapy kept a control over ...
... The 'baby-boom' of the 1960s and 1970s is largely ... services for people with an intellectual disability // ... reveals that the demand for intellectual disability services is ... of the best levels of service provided and huge ...
... was made at a major conference on brain tumours in ... , ,According to the Irish Cancer Society, in spite of ... rate of success and any damge to the delicate tissue ... there were 316 new cases of primary brain tumour diagnosed ...
... novel method of protection against bird flu has been studied and ... Rochester. // This involves a way of getting around the problem ... months to develop a vaccine. Also, two doses of vaccine would ... study is a" prime and boost" method of vaccination. An initial ...
... would be safer to carry out a stomach-stapling surgery by ... // ,Around 1 million bariatric surgeries ... recommended for weight loss and it involves stapling of the ... ,“Doing the surgery without incisions will make it ...
... mysterious viral outbreak has forced a Canadian University to shut ... This is thought to be a Norwalk-type virus that has ... New Brunswick and in the surrounding university town of Sackville. ... officials to investigate the outbreak. ,"They spent three hours on ...
Cached Medicine News:Health News:Awake Surgery to treat Brain tumours 2Health News:NOTE surgery – to combat obesit 2Health News:Mystery outbreak causes Canadian University to shut down 2
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the reporting of data ... Melphalan Hydrochloride for Injection with the Delcath Hepatic ... poster presentation at the Society of Surgical Oncology ...
(Date:3/26/2015)... WOODBRIDGE, ON , March 26, 2015 /PRNewswire/ - Pivotal ... specialty pharmaceutical company with a focus on Omega-3 therapies ... March 25, 2015 it issued 763,752 common shares of ... payment of interest for the period of December 5 ... on its outstanding Convertible Notes that is due on ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... 16, 2011 DecisionView Inc., a leading provider ... for life sciences companies, today announced that a ... Roche have agreed to participate in the creation ... based on real-world clinical performance data. Each of ...
... N.J., June 16, 2011 Ferring Pharmaceuticals Inc. proudly ... Houston in an effort to help increase awareness about ... of healthy aging. The NSG is ... and is organized by the National Senior Games Association, ...
Cached Medicine Technology:DecisionView to Create Clinical Trial Enrollment Benchmarks 2DecisionView to Create Clinical Trial Enrollment Benchmarks 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 2Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 4
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: